Global X Genomics & Biotechnology ETF (GNOM)

NASDAQ: GNOM · IEX Real-Time Price · USD
10.18
-0.13 (-1.26%)
At close: Sep 22, 2023, 4:00 PM
10.06
-0.12 (-1.18%)
After-hours: Sep 22, 2023, 6:51 PM EDT
-1.26%
Assets $143.89M
Expense Ratio 0.50%
PE Ratio n/a
Shares Out n/a
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return -19.01%
Volume 155,141
Open 10.31
Previous Close 10.31
Day's Range 10.16 - 10.31
52-Week Low 10.16
52-Week High 14.36
Beta n/a
Holdings 43
Inception Date Apr 5, 2019

About GNOM

Fund Home Page

The Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that is based on the Solactive Genomics index. The fund tracks an index of global biotech equities, selected and weighted by market cap. GNOM was launched on Apr 5, 2019 and is issued by Global X.

Asset Class Equity
Category Health
Stock Exchange NASDAQ
Ticker Symbol GNOM
Issuer Global X
Index Tracked Solactive Genomics Index

Top 10 Holdings

43.61% of assets
Name Symbol Weight
Sarepta Therapeutics, Inc. SRPT 5.18%
Genscript Biotech Corp Class H 1548.HK 4.56%
BioNTech SE BNTX 4.42%
Natera, Inc. NTRA 4.34%
CRISPR Therapeutics AG CRSP 4.33%
BioMarin Pharmaceutical Inc. BMRN 4.23%
Intellia Therapeutics, Inc. NTLA 4.23%
Pacific Biosciences of California, Inc. PACB 4.13%
Qiagen N.V. QGEN 4.12%
Veracyte, Inc. VCYT 4.09%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
2021-12-30 $0.00651 2022-01-07
2020-12-30 $0.0324 2021-01-08
Full Dividend History

News

As Biotech Adjusts to “New Normal,” Get Exposure With This ETF

Biotechnology was a much sought-after sector following the pandemic, but it's been having to adjust to a new normal since. Still, the sector offers growth potential as new and innovative biotechnology...

1 year ago - ETF Trends

ETF Battles: ARKG Vs IDNA Vs GNOM

Join us for a triple-header to determine the best genomics biotech ETF!

Other symbols: ARKGIDNA
2 years ago - ETFcom

Snag Next-Generation Tech Exposure with This Genomics ETF

ETF investors looking to get in on the next generation of medical technology may want to give the Global X Genomics & Biotechnology ETF (GNOM) a closer look. Genomic sequencing is already playing a pi...

2 years ago - ETF Trends

ETF Battles: ARKG Vs GNOM

Which biotech/genomics ETF is the better play?

Other symbols: ARKG
2 years ago - ETFcom

Can Global X's GNOM Be the Next Big ETF?

Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.

2 years ago - ETF Trends

Get On Board a Growing Biotech Industry With the GNOM ETF

It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over...

2 years ago - ETF Trends

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%...

Other symbols: IBBXBI
3 years ago - Market Watch

The Genomics Market is Poised for Growth Through 2025

Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-2...

Other symbols: ARKG
3 years ago - ETF Trends

Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.

Other symbols: CLOUHEROVGTXLK
3 years ago - CNBC

Biotech ETFs Surge After Invitae Acquires ArcherDX

Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic info...

Other symbols: ARKGXBI
3 years ago - ETF Trends

A Genomics ETF at the Center of the Coronavirus Fight

In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics ...

3 years ago - ETF Trends

3 Genomics ETFs Worth Jumping For

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliv...

Other symbols: ARKG
3 years ago - Benzinga

Declining Costs Boost Allure of GNOM Genomics ETF

Declining costs are viewed as one of the biggest factors driving the genomics and data suggest those costs continue falling, a scenario that could benefit ETFs, such as the Global X Genomics & Biotech...

3 years ago - ETF Trends

Why This Thematic Healthcare Could be a January Winner

Due in large part to the J.P. Morgan Health Care conference in San Francisco, the biotechnology industry’s marquee yearly confab, January is often a strong month for related equities and ETFs.

4 years ago - ETF Trends

This High Growth ETF May Not Be As Pricey As You Think

When it comes to growth stocks, investors often expect they will pay up to access that.

4 years ago - Benzinga

A Young Biotech ETF With Plenty of Potential

The Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted earlier this year, making it one of the newest additions to the biotech ETFs fray, but despite its rookie status, GNOM is a fund with a...

4 years ago - ETF Trends